TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06371586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy
Description: Albumin paclitaxel+SOX+BEV bi weekly neoadjuvant therapy for 6 cycles, with PD-1 monoclonal antibody therapy interspersed for 4 cycles. Review CT and gastroscopy every 3 cycles to evaluate the therapeutic effect. Patients who have been evaluated as effective after 6 cycles of treatment may consider surgery; Or continue the two-week regimen of albumin paclitaxel+bevacizumab for 3 cycles, while PD-1 monoclonal antibody for 2 cycles. Afterwards, the therapeutic effect will be evaluated, and surgery, radiotherapy, or maintenance medication treatment will be determined based on the therapeutic effect. Surgical patients begin adjuvant treatment 1-2 months after surgery based on the curative and pathological results of the surgery. Those who fail to evaluate during neoadjuvant therapy will undergo surgery or radiation therapy, or switch to a second-line systemic treatment plan.
Study: NCT05652803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bibliotherapy-based psychoeducation program
Description: In this study, the researcher aimed to gain awareness, skills and attitudes in order to help the participants reduce the negative consequences of depression and hopelessness. Based on the general purpose, a separate target has been established for each session of both intervention types. For bibliotherapy-based psychoeducation, story texts compatible with the goals were added to each session, and the psychoeducation part was supported by bibliotherapy. Considering the ability of the elderly to attend the training regularly, their attention and coordination, it was decided that the study would consist of 6 sessions and each session would be 60 minutes on average.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducation program
Description: The General Purpose of the Psychoeducation Program for Reducing Depression and Hopelessness: To help the participants gain awareness, skills and attitudes in order to help them reduce their depression and hopelessness levels.
Study: NCT05420831

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal
Description: Sacrospinous hysteropexy using the synthetic mesh

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic
Description: Laparoscopic Sacrohysteropexy
Study: NCT02441439

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Iron sucrose 200 mg
Description: I.V Iron sucrose 200 mg 2-3 times per week. Each time for 20-30 minutes

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose 500 mg
Description: I.V Iron sucrose 500 mg once per week. Each time for 3.5 hours
Study: NCT05440604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fortified milk
Description: Commercially available milk-based fortified beverage that has an updated profile of key micronutrients along with appropriate levels of protein and other macro- and micro- nutrients, in accordance with global and local nutritional recommendations
Study: NCT05048615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax 100 MG
Description: Patients will receive oral Venetoclax at a fixed dose of 100mg/day from day 1 to day 21 per cycle for a maximum of 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole capsule
Description: Patients will receive oral itraconazole at a dose of 100 mg every 12 hours from day 1 to day 21.
Study: NCT05470270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide
Description: Single administration of the new dispersible form of hydroxycarbamide at the usual dose in children with sickle cell disease who are already treated with the current form of hydroxycarbamide.
Study: NCT06103643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Using High Reality Simulator
Description: Using High Reality Simulator will perform emergency breech birth.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Using High Reality Simulator
Description: Using High Reality Simulator will perform emergency breech birth.
Study: NCT05989594

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based mobile guided exercise-based cardiac rehabilitation
Description: Discharge preparation, telerehabilitation, scheduled onsite follow-ups, telephone follow-ups, self-reporting, health education, online communication, family and peer support, mailing letters, institutional referrals, and security management.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Routine Care
Description: Discharge preparation, scheduled onsite follow-ups, telephone follow-ups
Study: NCT06240429

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen
Description: Daily doses of 10 g collagen peptide supplementation
Study: NCT04992754

Intervention type: BEHAVIORAL
Intervention: psychotherapy, lifestyle counseling
Description: psychotherapy, lifestyle counseling
Study: NCT05091957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Support Worker
Description: structured review of participant income supports with a trained CSW, to identify financial needs and benefits for which the family is eligible, including assessment of income and food security, affordability of medications, housing and energy insecurity, and dental care. The visits will be conducted in person, by telephone or by videoconferencing, according to participant preference and to ensure adherence to COVID-19 pandemic-related criteria.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in both groups will receive a written summary of available resources
Study: NCT05224843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)
Description: Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
Study: NCT04432792

Intervention type: OTHER
Intervention: Questionnaire
Description: Study survey participants will be administered 3 online surveys.
Study: NCT04872023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and bone marrow sampling
Description: Blood and bone marrow sampling
Study: NCT05121389

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: normal saline
Description: Normal saline is injected intravenously, using a infusion rate control device to control the drip rate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: Normal saline is injected intravenously, using a infusion rate control device to control the drip rate.
Study: NCT04897204

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Catheter ablation and left atrial appendage occlusion
Description: The patients underwent routine pulmonary vein isolation and linear ablation and left atrial appendage occlusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Additional left atrial appendage electrical isolation combined with catheter ablation and left atrial appendage occlusion
Description: These patients underwent routine pulmonary vein isolation and linear ablation and left atrial appendage occlusion, combined with additional left atrial appendage occlusion.
Study: NCT05244369

Intervention type: OTHER
Group type: OTHER
Intervention: Only TENS
Description: Rehabilitation program consisting of joint range of motion, stretching and strengthening exercises for 30 minutes, 5 days a week for only 4 weeks, and application of transcutaneous electrical nerve stimulation (TENS) to the tip of the stump

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture+TENS
Description: acupuncture application twice a week - a total of 8 sessions, rehabilitation program consisting of exercises 5 days a week for 4 weeks and transcutaneous electrical nerve stimulation (TENS) to the stump tip.
Study: NCT06252012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: The mobile application will be designed as a health assistant for women aged between 30-65 to encourage healthy choices and positively develop their behaviors regarding the prevention of cancer. Within the scope of the mobile application, information modules on cervical cancer screening tests, cervical cancer risk factors, ways to prevent cervical cancer, types of HPV, and HPV vaccine will be provided. A parallel-group pretest-posttest randomized controlled trial design will be used in the second stage of the study
Study: NCT05205070

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rosnilimab
Description: humanized monoclonal antibody

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution
Study: NCT03687008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Computer Based Intervention
Description: 25 sessions \[each 30-45 minutes, 5 days a week / for 5 weeks\], supervised by trained coaches
Study: NCT05137743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Apnea and Insomnia Relief (AIR)
Description: This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia.
Study: NCT05048615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Injection
Description: Patients will receive a maximum of two cycles of daily subcutaneous Azacitidine at a dose of 75 mg/m2 (maximum 100 mg) from day 1 to day 7.
Study: NCT05291923

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT02217670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg granules
Study: NCT05137743

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education (SE)
Description: This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
Study: NCT02217670

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 1000 mg film-coated tablets
Study: NCT05176925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg IV D1, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: The starting dose of sitravatinib in this study is 70 mg, oral once daily. After receiving 2 cycles of starting dose at 70 mg once daily with sitravatinib, if patients were tolerated well with study treatment (without AEs definitely related to sitravatinib nor TRAEs leading to sitravatinib dose reduction and interruption), it is recommended to escalate sitravatinib dose to 100 mg once daily at the discretion of the investigators after discussion with patients.
Study: NCT05394454

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bladder stimulation technique
Description: The bladder stimulation technique consists of two consecutive maneuvers. In the first maneuver, the bladder is stimulated by tapping the suprapubic region for 30 seconds at a frequency of 100 touches per minute. In the second maneuver, circular massage is applied to the paravertebral region for 30 seconds. The two stimulation maneuvers will be repeated alternately for 3 minutes (180 seconds) until micturition begins.
Study: NCT05626075

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Using Oculus Pentacam® which is s a rotating Scheimpflug camera. The rotational measuring procedure generates Scheimpflug images in three dimensions.
Description: Scheimpflug imaging attains a wide and high depth-of-focus , providing sharp images that include information from an anterior corneal surface through to the posterior crystalline capsule

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Using Oculus Pentacam® which is s a rotating Scheimpflug camera. The rotational measuring procedure generates Scheimpflug images in three dimensions.
Description: Scheimpflug imaging attains a wide and high depth-of-focus , providing sharp images that include information from an anterior corneal surface through to the posterior crystalline capsule

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Using Oculus Pentacam® which is s a rotating Scheimpflug camera. The rotational measuring procedure generates Scheimpflug images in three dimensions.
Description: Scheimpflug imaging attains a wide and high depth-of-focus , providing sharp images that include information from an anterior corneal surface through to the posterior crystalline capsule

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Using Oculus Pentacam® which is s a rotating Scheimpflug camera. The rotational measuring procedure generates Scheimpflug images in three dimensions.
Description: Scheimpflug imaging attains a wide and high depth-of-focus , providing sharp images that include information from an anterior corneal surface through to the posterior crystalline capsule
Study: NCT05647720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distalization combined with upper third molars extraction
Description: After surgical extraction of unerupted upper third molars, the maxillary first molars were distalized using a labial bow with two soldered crimpable hooks distal to the upper lateral incisors. The labial bow fitted in the flying tube of the upper first molar bands. It was anchored bilaterally to the infra-zygomatic mini-implant by closed coil spring that applied a force of 300gm on each side

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distalization without upper third molars extraction
Description: The maxillary first molars were distalized , without extracting upper third molars, using a labial bow with two soldered crimpable hooks distal to the upper lateral incisors. The labial bow fitted in the flying tube of the upper first molar bands. It was anchored bilaterally to the infra-zygomatic mini-implant by closed coil spring that applied a force of 300gm on each side
Study: NCT04386005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring Device
Description: The Dexcom G7 Glucose Monitoring System (San Diego, CA) reports continuous interstitial blood glucose concentrations every 5 minutes, does not require calibration, and involves only 1 needle stick to place the sensor. The manufacturer recommends that a single sensor may be used for up to 10 days. The Dexcom G7 system is the only FDA approved CGM system for children (age \>2 years).
Study: NCT06543420

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral reconstruction
Description: In lateral reconstruction group, lateral reconstruction is performed by suturing the levator ani muscle to the prostatic collateral ligament and fascia to strengthen the lateral posterior support structure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior reconstruction
Description: In posterior group, prior to completion of the operation, the posterior fibrous tissues of the sphincter are joined to the residual Denonvilliers fascia on the posterior bladder wall 1-2 cm cephalad and dorsally to the new bladder neck.
Study: NCT04803747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid (TXA)
Description: TXA 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9 % Saline)
Description: Placebo (0.9 % normal saline) 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
Study: NCT05688553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexi-bar
Description: two groups, experimental group intervention Flexi-bar with balance and strength training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: balance and strength training
Description: the control group intervention only balance and strength training
Study: NCT04763616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: The treatment cycle will be repeated up to 2 years. If a patient shows disease progression or unacceptable toxicity, the study treatment will be discontinued and followed up for efficacy and safety after the discontinuation of study treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: The treatment cycle will be repeated up to 2 years. If a patient shows disease progression or unacceptable toxicity, the study treatment will be discontinued and followed up for efficacy and safety after the discontinuation of study treatment.
Study: NCT05903638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction course
Description: 8-week, 26-hour, virtual mindfulness course
Study: NCT04936178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB003 tablets
Description: NB003 tablets will be administered at assigned doses for escalation phase and RP2D doses for expansion phase orally twice daily for repeated 28-day cycles until discontinuation criteria are met.
Study: NCT04893525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine/naloxone
Description: Buprenorphine/naloxone is a first line, evidence-based opioid agonist therapy that improves mortality for people with opioid use disorder, and that has been demonstrated to be effective at retaining people in addictions care and decreasing illicit opioid use when initiated from EDs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine/naloxone
Description: Buprenorphine/naloxone is a first line, evidence-based opioid agonist therapy that improves mortality for people with opioid use disorder, and that has been demonstrated to be effective at retaining people in addictions care and decreasing illicit opioid use when initiated from EDs.
Study: NCT05789576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTAMA (tapinarof) cream, 1%
Description: VTAMA (tapinarof) cream, 1% applied topically once daily
Study: NCT05678283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]CC-90010
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90010
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90010
Description: Specified dose on specified days
Study: NCT05655923

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ozonized olive oil
Description: ozonized oil will be mixed with xenograft in group II and Group III

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ozonized olive oil
Description: ozonized oil will be mixed with xenograft in group II and Group III

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: xenograft bone substitute
Description: Xenograft bone substitutes in all Groups

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: xenograft bone substitute
Description: Xenograft bone substitutes in all Groups

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: xenograft bone substitute
Description: Xenograft bone substitutes in all Groups
Study: NCT06009042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG 20g/d
Description: The dose of IVIG(intravenous immunoglobulin) is 20g/d. Participants also receive conventional liquid therapy and symptomatic and supportive treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG 10g/d
Description: The dose of IVIG(intravenous immunoglobulin) is 10g/d. Participants also receive conventional liquid therapy and symptomatic and supportive treatment.
Study: NCT05570812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (4-week ramp, 4-week steady dosing)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone
Description: (4-week ramp, 4-week steady dosing)
Study: NCT05144945

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Recombinant Influenza Vaccine (RIV4)
Description: Solution for intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent inactivated influenza vaccine (IIV4)
Description: Suspension for intramuscular injection
Study: NCT05878912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: The diet intervention delivers a weight loss program. The main component is a total diet replacement low energy diet. The intervention includes a gradual food reintroduction phase and maintenance strategies.
Study: NCT05933889

Intervention type: GENETIC
Intervention: Molecular Analysis
Description: Germline and circulating tumour DNA analysis of buccal/ blood samples and molecular analysis of primary and recurrent tumour tissue samples

Intervention type: OTHER
Intervention: Radiomic/ Morphological analysis
Description: Radiomic analysis and assessment of morphological features of pre-operative CT/ MRI imaging in patients who have undergone TORS for primary oropharyngeal cancer.
Study: NCT05675462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oncorine
Description: a modified human recombinant type 5 adenovirus with genetic modifications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: PD-1inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: TKI
Study: NCT05525507

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Conditioning and Stem cell infusion
Description: Patients will undergo a conditioning with TLI and ATG, followed by infusion of hematopoietic stem cells from the same HLA-identical donor that provided the original kidney
Study: NCT06231810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tactile stimulation
Description: Tactile stimuli of differing magnitudes will be applied